Navigation Links
Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Date:4/9/2013

Toronto, ON (PRWEB) April 09, 2013

The study will involve the location of mobile EEC at centers in three metropolitan areas in the US Midwest, US North East and in Canada, with several investigative sites at each node contributing subjects to the study. The screening and dosing will take place at the investigator site and the subject will be sent to the mobile EEC, located close to the investigator site, for EEC related activities. Inflamax will operate the mEEC™ and manage the study as a full service offering including site management, monitoring, data management, statistics and medical writing. Inflamax Research will employ its innovative electronic diary system (ePDAT™) and Online Recruiting Update Platform and subject referral system (OCRUP™) in the study.

This study which involves over 600 subjects and with plans for a one year follow on study will not commence until ATL has finalized partnership discussions.

“We selected Inflamax because of their unique ability to conduct high quality multicenter studies utilizing the EEC technology. I particularly like the ability to have key opinion leaders in the US able to participate in our EEC clinical trials, which has not been possible with fixed single center EEC studies up to now. We also like the advanced technology that Inflamax employs in the study conduct such as ePDAT and OCRUP™” says Manuel Llobet, ATL’s CEO.

“We are pleased to have been chosen by ATL to conduct this important study of their novel ultrashort allergy vaccine using our mobile EEC system. Our leading edge technologies such as ePDAT™ and OCRUP™ will provide a seamless transparent process that gives detailed real-time data of high quality to ATL regarding every aspect of the study from recruiting to final visit. The ePDAT diary cards will collect electronic data that has been shown to be the most accurate mode of symptom collection in the industry” say Dr Piyush Patel, CEO of Inflamax
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
2. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
3. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
4. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
5. Manchester leads the way in graphene membrane research
6. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
7. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
8. Solution Styrene Butadiene Rubber (S-SBR) Market is Expected to Reach USD 3.2 Billion in 2018: Transparency Market Research
9. Elsevier and the Belarus Ministry of Education Honor Researchers with Scopus Awards
10. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
11. Beekeepers, Researchers and Bayer CropScience Associate Overwintering Bee Losses with Varroa Mite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... A paper published today, " Financing ... in Science Translational Medicine, demonstrates the ... the risk associated with investing in the treatment ... of funding for developing so-called "orphan" drugs. ... between scientists at the National Center for Advancing ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... FamilyFarms Group is pleased to announce its valued ... received the 2015 Tomorrow’s Top Producer Horizon Award. The ... 35, who has demonstrated excellence in the business of ... Tomorrow's Top Producer Horizon Award. Every year I look ... and learning from their experiences. It is truly humbling ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... September 3 Debiopharm Group, SA,(Debiopharm), a Swiss-based ... the development of prescription drugs that target unmet ... to Dr Lluis,Quintana-Murci from the Institut Pasteur in ... field of evolutionary genetics of,infection. Funded by Debiopharm, ...
... Ontario, Sept. 3 Helix BioPharma Corp. (TSX, FSE: "HBP" ... chief operating officer, will present at the Rodman and Renshaw ... Sept. 9, at the New York Palace Hotel in New ... Company,s leading product development programs L-DOS47 and Topical Interferon Alpha-2b. ...
... Sept. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: ... China, announced today that,the State Food and Drug Administration ... vaccine, and has issued Sinovac a,production license for this ... which showed that PANFLU.1, Sinovac,s H1N1,vaccine, has a good ...
Cached Biology Technology:The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 2The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 3Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 3Sinovac Obtains Production License for H1N1 Vaccine 2Sinovac Obtains Production License for H1N1 Vaccine 3
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... Australian parents need to be educated about managing fever ... often unnecessarily, according to a Queensland University of Technology ... conducted the first study into how Australian parents, manage ... results were published in the latest Journal of Paediatrics ...
... 5 bioMETRX, Inc. (OTC,Bulletin Board: BMRX) a ... that it has acquired a patent that covers ... locks. The company believes that this patent ... years, consumers have been using portable locks, such ...
... of a science fiction thriller, researchers at UC Davis have ... of jaws located in the moray,s throat reaches forward into ... the esophagus for swallowing. "This is really an amazing ... Mehta, a postdoctoral researcher in the Section of Evolution and ...
Cached Biology News:Fever causing headaches for Aussie parents 2bioMETRX, Inc. Acquires Patent for Biometric Padlock 2'Alien' jaws help moray eels feed 2
Canine Chondrocytes (CnC) (500,000 cells)...
... Hex, Tet Cy3, Cy5, Texas Red, ... Hole Quenchers Molecular Beacons* ... 3 Dabcyl Dabcyl*Licensed from the ... labelled probes are purified either by HPLC ...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Roll of Mesh 5m x 25cm...
Biology Products: